Free Trial

Tourmaline Bio (TRML) News Today

Tourmaline Bio logo
$16.84 -0.28 (-1.64%)
Closing price 04:00 PM Eastern
Extended Trading
$17.94 +1.10 (+6.53%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Tourmaline Bio, Inc. stock logo
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by Analysts
Shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have been assigned a consensus rating of "Buy" from the eight research firms that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year pri
Tourmaline Bio, Inc. stock logo
Tourmaline Bio (NASDAQ:TRML) Given New $43.00 Price Target at Wedbush
Wedbush upped their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Friday.
Tourmaline Bio (TRML) Gets a Buy from Wedbush
Tourmaline Bio, Inc. stock logo
Tourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, HC Wainwright Analyst Says
HC Wainwright increased their price target on shares of Tourmaline Bio from $49.00 to $50.00 and gave the company a "buy" rating in a research report on Friday.
Tourmaline Bio price target raised to $43 from $42 at Wedbush
Tourmaline Bio, Inc. stock logo
Tourmaline Bio (NASDAQ:TRML) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS
Tourmaline Bio (NASDAQ:TRML - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.05.
Tourmaline Bio reports Q4 EPS (86c), consensus (87c)
Tourmaline Bio shares fall as Q4 loss widens
Tourmaline Bio sees cash runway into 2H27
Tourmaline Bio, Inc. stock logo
Tourmaline Bio (TRML) Projected to Post Earnings on Tuesday
Tourmaline Bio (NASDAQ:TRML) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.
Piper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)
Tourmaline Bio, Inc. stock logo
Wedbush Forecasts Tourmaline Bio FY2024 Earnings
Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued to investors on Thursday, March 6th. Wedbush analyst L. Chico anticipates that the company will earn ($2.78) per share for the year. Wedb
Wedbush bullish on Tourmaline Bio, initiates with an Outperform
Tourmaline Bio, Inc. stock logo
Tourmaline Bio (NASDAQ:TRML) Earns Outperform Rating from Analysts at Wedbush
Wedbush assumed coverage on shares of Tourmaline Bio in a research report on Thursday. They issued an "outperform" rating and a $42.00 price objective for the company.
Tourmaline Bio initiated with an Outperform at Wedbush
Truist Financial Sticks to Their Buy Rating for Tourmaline Bio (TRML)
Tourmaline Bio, Inc. stock logo
Lifesci Capital Estimates Tourmaline Bio FY2024 Earnings
Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities research analysts at Lifesci Capital issued their FY2024 earnings estimates for shares of Tourmaline Bio in a report issued on Monday, February 24th. Lifesci Capital analyst R. Katkhuda anticipates that the company will earn ($2.89) per
Tourmaline Bio initiated with an Outperform at LifeSci Capital
Tourmaline Bio, Inc. stock logo
Tourmaline Bio (NASDAQ:TRML) Now Covered by Analysts at Lifesci Capital
Lifesci Capital started coverage on Tourmaline Bio in a research report on Monday. They set an "outperform" rating and a $58.00 price target for the company.
Tourmaline Bio, Inc. stock logo
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by Analysts
Shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-mon
Tourmaline Bio, Inc. stock logo
Tourmaline Bio, Inc. (NASDAQ:TRML) Sees Large Growth in Short Interest
Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, an increase of 16.3% from the January 15th total of 2,330,000 shares. Based on an average trading volume of 248,100 shares, the days-to-cover ratio is currently 10.9 days. Currently, 17.4% of the shares of the stock are sold short.
Tourmaline Bio, Inc. stock logo
Leerink Partnrs Raises Earnings Estimates for Tourmaline Bio
Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($2.83
Tourmaline Bio, Inc. stock logo
Leerink Partnrs Comments on Tourmaline Bio FY2029 Earnings
Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Tourmaline Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will
Tourmaline Bio, Inc. stock logo
Jennison Associates LLC Has $17.15 Million Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)
Jennison Associates LLC lessened its position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 26.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 845,800 shares of the company's stock after selling 306,1
Tourmaline Bio management to meet with Cantor Fitzgerald
Tourmaline Bio, Inc. stock logo
Tourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Update
Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,080,000 shares, an increase of 26.8% from the December 31st total of 1,640,000 shares. Approximately 13.8% of the shares of the company are sold short. Based on an average trading volume of 197,500 shares, the days-to-cover ratio is presently 10.5 days.
Tourmaline Bio, Inc. stock logo
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from Brokerages
Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that
Tourmaline Bio, Inc. stock logo
Cantor Fitzgerald Comments on Tourmaline Bio FY2025 Earnings
Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Tourmaline Bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn (
Tourmaline Bio, Inc. stock logo
Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Rises By 26.8%
Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,080,000 shares, an increase of 26.8% from the December 15th total of 1,640,000 shares. Based on an average trading volume of 197,500 shares, the short-interest ratio is currently 10.5 days. Currently, 13.8% of the shares of the company are short sold.
Tourmaline Bio, Inc. stock logo
Barclays PLC Has $819,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML)
Barclays PLC raised its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 283.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,833 shares of the company's stock after purchasing
Tourmaline Bio, Inc. stock logo
Tourmaline Bio, Inc. (NASDAQ:TRML) Position Lifted by Geode Capital Management LLC
Geode Capital Management LLC grew its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 6.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 482,078 shares of the com
Tourmaline Bio, Inc. stock logo
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Rating of "Buy" by Analysts
Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been given a consensus rating of "Buy" by the six ratings firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price object
Tourmaline Bio, Inc. stock logo
State Street Corp Has $10.59 Million Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)
State Street Corp lifted its holdings in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 25.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 411,980 shares of the company's stock after acquir
Tourmaline Bio, Inc. stock logo
Tourmaline Bio (NASDAQ:TRML) Shares Down 3.9% - Should You Sell?
Tourmaline Bio (NASDAQ:TRML) Shares Down 3.9% - Should You Sell?
Tourmaline Bio, Inc. stock logo
Fmr LLC Has $387,000 Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)
Fmr LLC decreased its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 93.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,063 shares of the company's stock after
Tourmaline Bio, Inc. stock logo
Wellington Management Group LLP Raises Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)
Wellington Management Group LLP raised its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 72.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,741 shares of the company's stock aft
Remove Ads
Get Tourmaline Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.

TRML Media Mentions By Week

TRML Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TRML
News Sentiment

0.93

0.89

Average
Medical
News Sentiment

TRML News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TRML Articles
This Week

1

2

TRML Articles
Average Week

Remove Ads
Get Tourmaline Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:TRML) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners